Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Sanders

Nurse Practitioner, Family Tupelo, MS Nurse Practitioner

NPI 1124161849 CMS profile 10427963

4381 S Eason Blvd Ste 301, Tupelo, MS 38801

Open in the dashboard

General payments

$15,840

848 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Sanders of Tupelo, MS is reported in the CMS Open Payments database as having received $15,840 across 848 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,433 164
2024 General $3,215 148
2023 General $3,788 195
2022 General $3,261 187
2021 General $2,142 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Sanders
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Lisa Sanders were reported at $3,433. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Lisa Sanders Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,142 $124 $35–$379 $132
2022 $3,261 $141 $44–$430 $149
2023 $3,788 $154 $49–$476 $160
2024 $3,215 $165 $51–$504 $164
2025 $3,433 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,154 209 payments
  2. Pfizer Inc. $1,145 73 payments
  3. Biogen, Inc. $951 34 payments
  4. SK Life Science, Inc. $808 39 payments
  5. Novartis Pharmaceuticals Corporation $759 33 payments
  6. ACADIA Pharmaceuticals Inc $667 34 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $628 32 payments
  8. Alexion Pharmaceuticals, Inc. $560 25 payments
  9. Teva Pharmaceuticals USA, Inc. $557 22 payments
  10. UCB, Inc. $512 27 payments
  11. Other $6,099 320 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,431 839 payments
  2. Education $185 3 payments
  3. Consulting Fee $150 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $74 5 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $1,153 73 payments
  2. UBRELVY $1,130 81 payments
  3. NURTEC ODT Pain $1,016 70 payments
  4. NURTEC ODT Primary Care $1,012 57 payments
  5. BOTOX $749 40 payments
  6. NUPLAZID $667 34 payments
  7. KESIMPTA $665 28 payments
  8. ULTOMIRIS $383 15 payments
  9. VUMERITY $336 13 payments
  10. RYTARY $331 21 payments
  11. Other $9,034 473 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

6,542

Median for Nurse Practitioner: 389

Drug cost

$987,930

Median for Nurse Practitioner: $21,885

Branded share of claims

24.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 20 $186,302
Aimovig Autoinjector Erenumab-Aooe Brand 182 $137,181
Nurtec Odt Rimegepant Sulfate Brand 90 $128,042
Emgality Pen Galcanezumab-Gnlm Brand 98 $75,953
Trokendi Xr Topiramate Brand 11 $67,222
Qulipta Atogepant Brand 47 $56,764
Keppra Levetiracetam Brand 20 $38,223
Lacosamide Generic 170 $26,776
Levetiracetam Generic 555 $22,300
Briviact Brivaracetam Brand 13 $19,559

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$53,378

Medicare's payments for the services billed

Medicare patients

550

Average age 70

Services billed

789

334 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 36%
Diabetes 34%
Depression 31%
Chronic kidney disease 25%
Alzheimer's or dementia 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$325 — —
NURTEC ODT
$308 90 —
VUMERITY
$223 — —
ULTOMIRIS
$212 — —
KESIMPTA
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

848 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record